Fibrin targeting of echogenic liposomes with inactivated tissue plasminogen activator.
Fibrin-specific molecular targeting strategies are desirable for site-specific imaging and treatment of late stage atheroma, but fibrin-specific antibodies are difficult to produce and present immunogenicity problems. Tissue plasminogen activator (tPA) is an endogenous protein that has been shown to bind fibrin with high affinity and may circumvent antibody difficulties. Use of tPA-derived proteins or peptides, however, requires that the plasminogen-activating proteolytic activity be neutralized or removed. As an initial step in determining the feasibility of this targeting strategy, human recombinant tPA (Activase) was irreversibly inhibited with D-phe-L-pro-L-arg-chloromethyl ketone (PPACK) and conjugated to intrinsically echogenic liposomes (ELIP) by a thioether coupling protocol. Fibrin-binding affinities were assessed with a novel two-stage fibrin pad ELISA. We achieved 95-99% inactivation, while retaining both tPA fibrin-binding activities of K(D) approximately 2 nM and 33 nM. Thermodynamic analysis of the PPACK-inactivated tPA (tPA(P)) revealed highly exothermic interactions, indicative of ionic associations, especially for the higher affinity. The conjugation efficiency of tPA(P) to ELIP was within the range of that previously achieved for IgG and exhibited satisfactory fibrin targeting, characterized by striking increases of enthalpy and entropy increments. Evidence for coupling of noncovalent association energetics with the phosphatidylethanolamine major phase transition, observed in previous IgG antibody conjugations, was also evident in this case, but the nature of the transduction mechanism was different. These results demonstrate that tPA-derived components lacking proteolytic activity can be employed as fibrin-targeting agents for delivery of therapeutic and diagnostic formulations.
Division of Cardiology, Department of Internal Medicine, University of Texas Health Science Center-Houston, Houston, TX 77030, USA. E.Klegerman@uth.tmc.edu
Melvin E
ME
Klegerman
Yuejiao
Y
Zou
David D
DD
McPherson
D000590:Amino Acid Chloromethyl Ketones / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology; D000818:Animals; D000906:Antibodies / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology; D000915:Antibody Affinity / Q000276:immunology; D050197:Atherosclerosis / Q000000981:diagnostic imaging* / Q000276:immunology; D003287:Contrast Media / Q000737:chemistry / Q000494:pharmacology*; D016503:Drug Delivery Systems / Q000379:methods; D004789:Enzyme Activation / Q000187:drug effects; D005337:Fibrin / Q000737:chemistry / Q000276:immunology; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D006801:Humans; D008081:Liposomes; D015842:Serine Proteinase Inhibitors / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D014463:Ultrasonography
D000590:Amino Acid Chloromethyl Ketones; D000906:Antibodies; D003287:Contrast Media; D005343:Fibrinolytic Agents; D008081:Liposomes; D015842:Serine Proteinase Inhibitors; D005337:Fibrin; D010959:Tissue Plasminogen Activator; C040308:phenylalanyl-prolyl-arginine-chloromethyl ketone